xvivo perfusion - XVIPF

XVIPF

Close Chg Chg %
23.85 -0.33 -1.38%

Closed Market

23.52

-0.33 (1.38%)

Volume: 519.00

Last Updated:

Feb 5, 2026, 11:21 AM EDT

Company Overview: xvivo perfusion - XVIPF

XVIPF Key Data

Open

$23.79

Day Range

23.52 - 23.79

52 Week Range

16.98 - 44.00

Market Cap

$721.02M

Shares Outstanding

31.50M

Public Float

24.74M

Beta

1.87

Rev. Per Employee

N/A

P/E Ratio

288.59

EPS

$0.09

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

108.91

 

XVIPF Performance

1 Week
 
-7.74%
 
1 Month
 
13.62%
 
3 Months
 
23.45%
 
1 Year
 
-51.04%
 
5 Years
 
N/A
 

XVIPF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About xvivo perfusion - XVIPF

Xvivo Perfusion AB is a medical technology company. It involves in developing and marketing solutions and systems for assessing the usability of organs, and maintaining organs in good condition outside the body pending transplantation. Its products include XPS, XPS Disposable Kit, Steen Solution, Organ Chamber, Lung Cannula Set, Perfadex and Silicone Tubing Set. It operates through the Durable Goods and Non-Durable Goods segments. The Durable Goods segment includes sales and rental revenues from machines. The Non-Durable Goods segment covers sales of goods and services that are not durable goods. The company was founded by Magnus Nilsson on December 17, 1998 and is headquartered in Gothenburg, Sweden.

XVIPF At a Glance

Xvivo Perfusion AB
Mässans gata 10
Gothenburg, Vastra Gotaland 412 51
Phone 46-31-788-21-50 Revenue 82.81M
Industry Medical Specialties Net Income 2.57M
Sector Health Technology 2025 Sales Growth 6.459%
Fiscal Year-end 12 / 2026 Employees 198
View SEC Filings

XVIPF Valuation

P/E Current 280.859
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 248.359
Price to Sales Ratio 7.713
Price to Book Ratio 2.781
Price to Cash Flow Ratio 61.98
Enterprise Value to EBITDA 37.289
Enterprise Value to Sales 7.494
Total Debt to Enterprise Value 0.022

XVIPF Efficiency

Revenue/Employee 418,234.994
Income Per Employee 12,958.016
Receivables Turnover 5.17
Total Asset Turnover 0.349

XVIPF Liquidity

Current Ratio 5.765
Quick Ratio 3.684
Cash Ratio 2.447

XVIPF Profitability

Gross Margin 65.688
Operating Margin 11.453
Pretax Margin 4.748
Net Margin 3.098
Return on Assets 1.08
Return on Equity 1.209
Return on Total Capital 1.057
Return on Invested Capital 1.169

XVIPF Capital Structure

Total Debt to Total Equity 5.901
Total Debt to Total Capital 5.572
Total Debt to Total Assets 5.253
Long-Term Debt to Equity 5.354
Long-Term Debt to Total Capital 5.056
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Xvivo Perfusion - XVIPF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
41.04M 56.29M 77.79M 82.81M
Sales Growth
+36.34% +37.16% +38.20% +6.46%
Cost of Goods Sold (COGS) incl D&A
13.05M 17.01M 25.68M 28.41M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.56M 2.91M 6.38M 7.16M
Depreciation
1.41M 2.19M 3.07M 4.01M
Amortization of Intangibles
148.91K 716.94K 3.31M 3.15M
COGS Growth
+10.40% +30.43% +50.91% +10.66%
Gross Income
27.99M 39.27M 52.11M 54.40M
Gross Income Growth
+53.11% +40.30% +32.69% +4.39%
Gross Profit Margin
+68.21% +69.77% +66.99% +65.69%
2022 2023 2024 2025 5-year trend
SG&A Expense
26.16M 35.65M 41.18M 44.91M
Research & Development
6.39M 12.18M 10.68M 10.27M
Other SG&A
19.77M 23.47M 30.50M 34.65M
SGA Growth
+39.24% +36.23% +15.52% +9.07%
Other Operating Expense
- - - -
-
Unusual Expense
1.41M 3.63M 2.58M 820.19K
EBIT after Unusual Expense
418.58K (3.39K) 8.35M 8.66M
Non Operating Income/Expense
1.89M 9.02M 11.09M (208.41K)
Non-Operating Interest Income
- 209.78K 833.65K 1.62M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
108.10K 112.10K 529.76K 4.52M
Interest Expense Growth
+236.25% +3.69% +372.60% +753.95%
Gross Interest Expense
108.10K 112.10K 529.76K 4.52M
Interest Capitalized
- - - -
-
Pretax Income
2.20M 8.90M 18.91M 3.93M
Pretax Income Growth
+184.00% +303.80% +112.40% -79.21%
Pretax Margin
+5.37% +15.82% +24.31% +4.75%
Income Tax
384.09K 254.43K 2.63M 1.37M
Income Tax - Current - Domestic
- 90.42K 1.36M 778.32K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- 293.68K (1.10M) 1.85M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.82M 8.65M 16.29M 2.57M
Minority Interest Expense
- - - -
-
Net Income
1.82M 8.65M 16.29M 2.57M
Net Income Growth
+91.75% +375.01% +88.29% -84.25%
Net Margin Growth
+4.44% +15.37% +20.94% +3.10%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.82M 8.65M 16.29M 2.57M
Preferred Dividends
- - - -
-
Net Income Available to Common
1.82M 8.65M 16.29M 2.57M
EPS (Basic)
0.0617 0.2889 0.517 0.0815
EPS (Basic) Growth
+87.54% +368.23% +78.95% -84.24%
Basic Shares Outstanding
29.53M 29.94M 31.50M 31.50M
EPS (Diluted)
0.0617 0.2889 0.5145 0.0813
EPS (Diluted) Growth
+88.11% +368.23% +78.09% -84.20%
Diluted Shares Outstanding
29.53M 29.94M 31.65M 31.56M
EBITDA
3.39M 6.53M 17.31M 16.64M
EBITDA Growth
+4.31% +92.86% +164.92% -3.86%
EBITDA Margin
+8.26% +11.61% +22.25% +20.10%

Xvivo Perfusion in the News